ORBITA-2 - Percutaneous coronary intervention for stable angina

Luis Ortega Paz interviews Rasha Al-Lamee and Christopher Rajkumar on the results of ORBITA-2 randomized placebo-controlled trial, which were presented at the AHA 2023 Congress in Philadelphia.
In stable angina patients with minimal antianginal medication and objective evidence of ischemia, PCI improved angina symptoms more than a placebo procedure, indicating better angina-related health.
Read more news from #AHA 2023 here:
www.pcronline....

[@arshadali-qn9fw]

Fantastic study pattern and result

[@delwoodkelp8590]

Nice interview. As a pci patient, I was wondering if any patients in the pci wing ...with a bifurcation stent placement were included? AND how such a sub-group fared after 12 weeks. Possibly including any with a jailed side branch.
Or were such cases excluded?

[@elkammash]

Good effort but unfair to compare pci to placebo. Also PCI patients will remain on OMT

[@luigibirillo6629]

PCI is better than nothing